ATOLL 2010

1 Treatments

**Studied treatment**  IV enoxaparin
IV enoxaparin at 0.5 mg/kg, whether or not GP IIb/IIIa inhibitors are used without coagulation monitoring

**Control treatment**  UFH
UFH at 50 to 70 IU/kg with or 70 to 100 IU without GP IIb/IIIa inhibitors, with dosage titrated to coagulation monitoring

**Concomitant treatments**  -

**Antiplatelet drugs**  -

**Age (mean), years**  59 years (median)

**male (%)**  78%

**UFH as Antithrombin during PCI (%)**  -

**Enoxaparin as Antithrombin during PCI**  -

**Bivalirudin as Antithrombin during PCI**  -

**stent implanted (%)**  96%

**Drug-eluting stent implanted**  -

2 Patients

**Patients**  patients undergoing PCI for acute STEMI

**Inclusion criteria**  -

**Exclusion criteria**  -

**Diabetes (%)**  14%

**Previous myocardial infarction (%)**  -

**Previous PCI**  -

**Previous CABG**  -

**Weight (kg)**  -

**Hypertension (%)**  -

**Hyperlipidaemia**  -
Current smoker -
Unstable angina / ACS -
Multivessel coronary disease -

3 Methods
Blinding open

Design Parallel groups

Centers 43

Geographical area Austria, France, Germany, and US

Sizes 450/460

Attempted lesions per patient (mean) -

Left main coronary a x-bitm -
Left anterior descending coronary artery -
Left circumfl ex coronary artery -
Right coronary artery -

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>death, MI, revascularization</td>
<td>-450</td>
<td>-460</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>All cause death</td>
<td>-450</td>
<td>-460</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>Ischaemic complication</td>
<td>-450</td>
<td>-460</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>MI</td>
<td>-450</td>
<td>-460</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>Unplanned revascularisation for ischaemia</td>
<td>-450</td>
<td>-460</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>death, MI, urgent TVR, in-hospital major bleeding</td>
<td>-450</td>
<td>-460</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>net benefit</td>
<td>-450</td>
<td>-460</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>minor bleeding</td>
<td>-450</td>
<td>-460</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>major bleeding</td>
<td>-450</td>
<td>-460</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>safety criteria</td>
<td>-450</td>
<td>-460</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>

5 References